EXHIBIT 99.1
FOR IMMEDIATE RELEASE:

              AMERICAN BIO MEDICA APPOINTS DANIEL W. KOLLIN TO ITS
                               BOARD OF DIRECTORS

KINDERHOOK, NY, February 12, 2003 - American Bio Medica Corporation
(NASDAQ:ABMC) today announced that at a regular meeting held on February 5,
2003, the ABMC Board of Directors appointed Daniel W. Kollin to serve as a
member of its Board of Directors. Kollin's appointment brings the total number
of ABMC board members to seven.

Mr. Kollin, 61, is a principal of BioMed Capital Group, Ltd., a firm that
provides strategic and business advisory services. Kollin has over twenty years
experience in investment banking, venture capital and corporate management,
specializing in pharmaceutical, biotechnology and healthcare companies in North
America and Europe. Kollin previously served as a Vice President of
Prudential-Bache Capital Funding and Director of Corporate Finance and partner
of Whale Securities Corp. Before his involvement in the financial services
industry, Kollin held marketing, planning and development executive positions
with Becton-Dickinson and Co. and Sandoz, Inc.

Mr. Kollin currently serves on the Board of Directors of GenSci Regeneration
Sciences Inc. (TORONTO:GNS.TO). He received his MBA from The Wharton School of
the University of Pennsylvania.

Gerald A. Moore, Chairman and Chief Executive Officer of ABMC commented, "We are
proud to have a professional of Dan's caliber join our Board of Directors. He
brings extensive strategic financial and management expertise in the fields of
healthcare and biotechnology. We are confident he will be an important asset to
our Board of Directors." Moore added, "The addition of Dan further enhances the
independent structure of our board, bringing the number of independent directors
to four."

About American Bio Medica Corporation

American Bio Medica Corporation is a biotechnology company that develops,
manufactures and markets inexpensive, accurate, immunoassay diagnostic test
kits, including some of the world's most effective on-site drugs of abuse tests.
The company and its worldwide distribution network target the workplace,
government, corrections, clinical and educational markets. ABMC's Rapid Drug
Screen(R), Rapid One(R), and Rapid Tec(TM) test for the presence or absence of
drugs of abuse in urine, while OralStat6(R) tests for the presence or absence of
drugs of abuse in saliva. ABMC was recently named among the 2002 Deloitte &
Touche Technology Fast 500, a listing of the fastest-growing technology
companies in North America.

This release may contain forward-looking statements. These forward-looking
statements involve risks and uncertainties that could cause actual results to
differ, and such differences could be material. Such risks and uncertainties
include, but are not limited to, the following: continued acceptance of the
Company's products, increased levels of competition in our industry, the
acceptance of new products, inherent risks associated with product development
and intellectual property rights, the Company's dependence on key personnel,
third party sales and suppliers. There can be no assurance that the Company will
be successful in addressing such risks and uncertainties. Investors are strongly
encouraged to review the section entitled "Risk Factors" in the Company's annual
report on Form 10-KSB for the transition period ended December 31, 2001, and
quarterly reports on Form 10-QSB on file with the Securities and Exchange
Commission for a discussion of risks and uncertainties that could affect
operating results and the market price of the Company's common shares.